CRISPR Therapeutics (CRSP) Competitors

CRISPR Therapeutics (NASDAQ:CRSP) and Neurocrine Biosciences (NASDAQ:NBIX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

Do insiders and institutionals hold more shares of CRSP or NBIX?

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 4.3% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 4.8% of Neurocrine Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Does the MarketBeat Community believe in CRSP or NBIX?

Neurocrine Biosciences received 559 more outperform votes than CRISPR Therapeutics when rated by MarketBeat users. Likewise, 77.70% of users gave Neurocrine Biosciences an outperform vote while only 64.29% of users gave CRISPR Therapeutics an outperform vote.

Company	Underperform	Outperform
CRISPR Therapeutics	Outperform Votes 486 64.29%	Underperform Votes 270 35.71%
Neurocrine Biosciences	Outperform Votes 1045 77.70%	Underperform Votes 300 22.30%

Do analysts rate CRSP or NBIX?

CRISPR Therapeutics currently has a consensus price target of $71.75, suggesting a potential upside of 73.48%. Neurocrine Biosciences has a consensus price target of $162.00, suggesting a potential upside of 30.24%. Given CRISPR Therapeutics' higher probable upside, equities research analysts clearly believe CRISPR Therapeutics is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.50
Neurocrine Biosciences	0 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.86

Which has preferable valuation and earnings, CRSP or NBIX?

Neurocrine Biosciences has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$35M	102.06	-$366.25M	-$4.52	-9.15
Neurocrine Biosciences	$2.41B	5.10	$341.30M	$2.95	42.17

Does the media refer more to CRSP or NBIX?

In the previous week, Neurocrine Biosciences had 9 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 22 mentions for Neurocrine Biosciences and 13 mentions for CRISPR Therapeutics. Neurocrine Biosciences' average media sentiment score of 1.05 beat CRISPR Therapeutics' score of 0.95 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurocrine Biosciences	11 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is CRSP or NBIX more profitable?

Neurocrine Biosciences has a net margin of 14.49% compared to CRISPR Therapeutics' net margin of -981.54%. Neurocrine Biosciences' return on equity of 13.38% beat CRISPR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-981.54%	-18.46%	-15.79%
Neurocrine Biosciences	14.49%	13.38%	9.73%

Which has more risk & volatility, CRSP or NBIX?

CRISPR Therapeutics has a beta of 1.75, suggesting that its stock price is 75% more volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500.

Summary

Neurocrine Biosciences beats CRISPR Therapeutics on 15 of the 18 factors compared between the two stocks.